Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease
<p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-An...
Ausführliche Beschreibung
Autor*in: |
Polilli Ennio [verfasserIn] Ursini Tamara [verfasserIn] Mazzotta Elena [verfasserIn] Sozio Federica [verfasserIn] Savini Vincenzo [verfasserIn] D'Antonio Domenico [verfasserIn] Barbato Michelino [verfasserIn] Consorte Augusta [verfasserIn] Parruti Giustino [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2012 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Annals of Clinical Microbiology and Antimicrobials - BMC, 2003, 11(2012), 1, p 6 |
---|---|
Übergeordnetes Werk: |
volume:11 ; year:2012 ; number:1, p 6 |
Links: |
---|
DOI / URN: |
10.1186/1476-0711-11-6 |
---|
Katalog-ID: |
DOAJ025167022 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ025167022 | ||
003 | DE-627 | ||
005 | 20230502141827.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2012 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/1476-0711-11-6 |2 doi | |
035 | |a (DE-627)DOAJ025167022 | ||
035 | |a (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
050 | 0 | |a RC109-216 | |
050 | 0 | |a QR1-502 | |
100 | 0 | |a Polilli Ennio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< | ||
650 | 4 | |a Methicillin-resistant <it<Staphylococcus aureus</it< | |
650 | 4 | |a Osteomyelitis | |
650 | 4 | |a Daptomycin | |
650 | 4 | |a Salvage therapy | |
650 | 4 | |a Antibiotic therapy | |
653 | 0 | |a Therapeutics. Pharmacology | |
653 | 0 | |a Infectious and parasitic diseases | |
653 | 0 | |a Microbiology | |
700 | 0 | |a Ursini Tamara |e verfasserin |4 aut | |
700 | 0 | |a Mazzotta Elena |e verfasserin |4 aut | |
700 | 0 | |a Sozio Federica |e verfasserin |4 aut | |
700 | 0 | |a Savini Vincenzo |e verfasserin |4 aut | |
700 | 0 | |a D'Antonio Domenico |e verfasserin |4 aut | |
700 | 0 | |a Barbato Michelino |e verfasserin |4 aut | |
700 | 0 | |a Consorte Augusta |e verfasserin |4 aut | |
700 | 0 | |a Parruti Giustino |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Annals of Clinical Microbiology and Antimicrobials |d BMC, 2003 |g 11(2012), 1, p 6 |w (DE-627)359783430 |w (DE-600)2097873-X |x 14760711 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2012 |g number:1, p 6 |
856 | 4 | 0 | |u https://doi.org/10.1186/1476-0711-11-6 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/1c39504792544743b3ae27efa8f48086 |z kostenfrei |
856 | 4 | 0 | |u http://www.ann-clinmicrob.com/content/11/1/6 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1476-0711 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 11 |j 2012 |e 1, p 6 |
author_variant |
p e pe u t ut m e me s f sf s v sv d d dd b m bm c a ca p g pg |
---|---|
matchkey_str |
article:14760711:2012----::ucsflavgteayihatmcnootoyltsasdyehclirssatttpyoocsuestnrnlr |
hierarchy_sort_str |
2012 |
callnumber-subject-code |
RM |
publishDate |
2012 |
allfields |
10.1186/1476-0711-11-6 doi (DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Polilli Ennio verfasserin aut Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Ursini Tamara verfasserin aut Mazzotta Elena verfasserin aut Sozio Federica verfasserin aut Savini Vincenzo verfasserin aut D'Antonio Domenico verfasserin aut Barbato Michelino verfasserin aut Consorte Augusta verfasserin aut Parruti Giustino verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 11(2012), 1, p 6 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:11 year:2012 number:1, p 6 https://doi.org/10.1186/1476-0711-11-6 kostenfrei https://doaj.org/article/1c39504792544743b3ae27efa8f48086 kostenfrei http://www.ann-clinmicrob.com/content/11/1/6 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2012 1, p 6 |
spelling |
10.1186/1476-0711-11-6 doi (DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Polilli Ennio verfasserin aut Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Ursini Tamara verfasserin aut Mazzotta Elena verfasserin aut Sozio Federica verfasserin aut Savini Vincenzo verfasserin aut D'Antonio Domenico verfasserin aut Barbato Michelino verfasserin aut Consorte Augusta verfasserin aut Parruti Giustino verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 11(2012), 1, p 6 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:11 year:2012 number:1, p 6 https://doi.org/10.1186/1476-0711-11-6 kostenfrei https://doaj.org/article/1c39504792544743b3ae27efa8f48086 kostenfrei http://www.ann-clinmicrob.com/content/11/1/6 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2012 1, p 6 |
allfields_unstemmed |
10.1186/1476-0711-11-6 doi (DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Polilli Ennio verfasserin aut Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Ursini Tamara verfasserin aut Mazzotta Elena verfasserin aut Sozio Federica verfasserin aut Savini Vincenzo verfasserin aut D'Antonio Domenico verfasserin aut Barbato Michelino verfasserin aut Consorte Augusta verfasserin aut Parruti Giustino verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 11(2012), 1, p 6 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:11 year:2012 number:1, p 6 https://doi.org/10.1186/1476-0711-11-6 kostenfrei https://doaj.org/article/1c39504792544743b3ae27efa8f48086 kostenfrei http://www.ann-clinmicrob.com/content/11/1/6 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2012 1, p 6 |
allfieldsGer |
10.1186/1476-0711-11-6 doi (DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Polilli Ennio verfasserin aut Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Ursini Tamara verfasserin aut Mazzotta Elena verfasserin aut Sozio Federica verfasserin aut Savini Vincenzo verfasserin aut D'Antonio Domenico verfasserin aut Barbato Michelino verfasserin aut Consorte Augusta verfasserin aut Parruti Giustino verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 11(2012), 1, p 6 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:11 year:2012 number:1, p 6 https://doi.org/10.1186/1476-0711-11-6 kostenfrei https://doaj.org/article/1c39504792544743b3ae27efa8f48086 kostenfrei http://www.ann-clinmicrob.com/content/11/1/6 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2012 1, p 6 |
allfieldsSound |
10.1186/1476-0711-11-6 doi (DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Polilli Ennio verfasserin aut Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Ursini Tamara verfasserin aut Mazzotta Elena verfasserin aut Sozio Federica verfasserin aut Savini Vincenzo verfasserin aut D'Antonio Domenico verfasserin aut Barbato Michelino verfasserin aut Consorte Augusta verfasserin aut Parruti Giustino verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 11(2012), 1, p 6 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:11 year:2012 number:1, p 6 https://doi.org/10.1186/1476-0711-11-6 kostenfrei https://doaj.org/article/1c39504792544743b3ae27efa8f48086 kostenfrei http://www.ann-clinmicrob.com/content/11/1/6 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2012 1, p 6 |
language |
English |
source |
In Annals of Clinical Microbiology and Antimicrobials 11(2012), 1, p 6 volume:11 year:2012 number:1, p 6 |
sourceStr |
In Annals of Clinical Microbiology and Antimicrobials 11(2012), 1, p 6 volume:11 year:2012 number:1, p 6 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology |
isfreeaccess_bool |
true |
container_title |
Annals of Clinical Microbiology and Antimicrobials |
authorswithroles_txt_mv |
Polilli Ennio @@aut@@ Ursini Tamara @@aut@@ Mazzotta Elena @@aut@@ Sozio Federica @@aut@@ Savini Vincenzo @@aut@@ D'Antonio Domenico @@aut@@ Barbato Michelino @@aut@@ Consorte Augusta @@aut@@ Parruti Giustino @@aut@@ |
publishDateDaySort_date |
2012-01-01T00:00:00Z |
hierarchy_top_id |
359783430 |
id |
DOAJ025167022 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ025167022</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502141827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-0711-11-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ025167022</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1c39504792544743b3ae27efa8f48086</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Polilli Ennio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Methicillin-resistant <it<Staphylococcus aureus</it<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Osteomyelitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daptomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Salvage therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibiotic therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursini Tamara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mazzotta Elena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sozio Federica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Savini Vincenzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D'Antonio Domenico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbato Michelino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Consorte Augusta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parruti Giustino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Annals of Clinical Microbiology and Antimicrobials</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">11(2012), 1, p 6</subfield><subfield code="w">(DE-627)359783430</subfield><subfield code="w">(DE-600)2097873-X</subfield><subfield code="x">14760711</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1, p 6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1476-0711-11-6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1c39504792544743b3ae27efa8f48086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ann-clinmicrob.com/content/11/1/6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1476-0711</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2012</subfield><subfield code="e">1, p 6</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Polilli Ennio |
spellingShingle |
Polilli Ennio misc RM1-950 misc RC109-216 misc QR1-502 misc Methicillin-resistant <it<Staphylococcus aureus</it< misc Osteomyelitis misc Daptomycin misc Salvage therapy misc Antibiotic therapy misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
authorStr |
Polilli Ennio |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)359783430 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
14760711 |
topic_title |
RM1-950 RC109-216 QR1-502 Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease Methicillin-resistant <it<Staphylococcus aureus</it< Osteomyelitis Daptomycin Salvage therapy Antibiotic therapy |
topic |
misc RM1-950 misc RC109-216 misc QR1-502 misc Methicillin-resistant <it<Staphylococcus aureus</it< misc Osteomyelitis misc Daptomycin misc Salvage therapy misc Antibiotic therapy misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology |
topic_unstemmed |
misc RM1-950 misc RC109-216 misc QR1-502 misc Methicillin-resistant <it<Staphylococcus aureus</it< misc Osteomyelitis misc Daptomycin misc Salvage therapy misc Antibiotic therapy misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology |
topic_browse |
misc RM1-950 misc RC109-216 misc QR1-502 misc Methicillin-resistant <it<Staphylococcus aureus</it< misc Osteomyelitis misc Daptomycin misc Salvage therapy misc Antibiotic therapy misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Annals of Clinical Microbiology and Antimicrobials |
hierarchy_parent_id |
359783430 |
hierarchy_top_title |
Annals of Clinical Microbiology and Antimicrobials |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)359783430 (DE-600)2097873-X |
title |
Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
ctrlnum |
(DE-627)DOAJ025167022 (DE-599)DOAJ1c39504792544743b3ae27efa8f48086 |
title_full |
Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
author_sort |
Polilli Ennio |
journal |
Annals of Clinical Microbiology and Antimicrobials |
journalStr |
Annals of Clinical Microbiology and Antimicrobials |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2012 |
contenttype_str_mv |
txt |
author_browse |
Polilli Ennio Ursini Tamara Mazzotta Elena Sozio Federica Savini Vincenzo D'Antonio Domenico Barbato Michelino Consorte Augusta Parruti Giustino |
container_volume |
11 |
class |
RM1-950 RC109-216 QR1-502 |
format_se |
Elektronische Aufsätze |
author-letter |
Polilli Ennio |
doi_str_mv |
10.1186/1476-0711-11-6 |
author2-role |
verfasserin |
title_sort |
successful salvage therapy with daptomycin for osteomyelitis caused by methicillin-resistant <it<staphylococcus aureus </it<in a renal transplant recipient with fabry-anderson disease |
callnumber |
RM1-950 |
title_auth |
Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
abstract |
<p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< |
abstractGer |
<p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< |
abstract_unstemmed |
<p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1, p 6 |
title_short |
Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease |
url |
https://doi.org/10.1186/1476-0711-11-6 https://doaj.org/article/1c39504792544743b3ae27efa8f48086 http://www.ann-clinmicrob.com/content/11/1/6 https://doaj.org/toc/1476-0711 |
remote_bool |
true |
author2 |
Ursini Tamara Mazzotta Elena Sozio Federica Savini Vincenzo D'Antonio Domenico Barbato Michelino Consorte Augusta Parruti Giustino |
author2Str |
Ursini Tamara Mazzotta Elena Sozio Federica Savini Vincenzo D'Antonio Domenico Barbato Michelino Consorte Augusta Parruti Giustino |
ppnlink |
359783430 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/1476-0711-11-6 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T13:23:25.096Z |
_version_ |
1803564356837834752 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ025167022</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502141827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-0711-11-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ025167022</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1c39504792544743b3ae27efa8f48086</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Polilli Ennio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant <it<Staphylococcus aureus </it<in a renal transplant recipient with Fabry-Anderson disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Daptomycin is licensed in adults for the management of <it<Staphylococcus aureus </it<methicillin-resistant infections, including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/qd for 4 weeks. Local debridement was performed in advance of each line of treatment.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Methicillin-resistant <it<Staphylococcus aureus</it<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Osteomyelitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daptomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Salvage therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibiotic therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursini Tamara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mazzotta Elena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sozio Federica</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Savini Vincenzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D'Antonio Domenico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbato Michelino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Consorte Augusta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parruti Giustino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Annals of Clinical Microbiology and Antimicrobials</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">11(2012), 1, p 6</subfield><subfield code="w">(DE-627)359783430</subfield><subfield code="w">(DE-600)2097873-X</subfield><subfield code="x">14760711</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1, p 6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1476-0711-11-6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1c39504792544743b3ae27efa8f48086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ann-clinmicrob.com/content/11/1/6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1476-0711</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2012</subfield><subfield code="e">1, p 6</subfield></datafield></record></collection>
|
score |
7.400324 |